Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Japan Prize Laureates Announced21.1.2026 07:00:00 EET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. (JST) on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Scie
Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support21.1.2026 05:12:00 EET | Press release
Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capability designed to support evidence-based clinical decision-making. The service is available free of charge to clinicians and medical students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120591991/en/ AQ’s PC platform provides medical professionals with two core capabilities: Health Q&A and DeepSearch. It supports medical literature search, clinical practice, and research, helping reduce clinicians’ day-to-day workload while improving access to high-quality medical information. To ensure accuracy and reliability, AQ rigorously curates its sources based on recognized levels of evidence. The platform integrates more than 36 million high-quality Chinese and international medical publications, making its clinical decision support closely aligned with real-world practice. Deep
NIKE, Inc. Announces New Geography Leadership Appointments20.1.2026 23:15:00 EET | Press release
NIKE, Inc. (NYSE: NKE) today shared the following note with teammates regarding changes to its Senior Leadership Team: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120575539/en/ César Garcia, VP/GM Nike Europe, Middle East and Africa (EMEA) To: Lst-Global From: EHill Subject: Leadership Announcements Team, In recent months, the Senior Leadership Team has benefited from having our Geography VP/GMs at the table helping us move faster and bringing us closer to athletes* in both countries and marketplaces around the world. As we continue to drive our Win Now actions and stand up our Sport Offense, I’d like to share several important leadership changes across three of our Geo VP/GM roles. EMEA Carl Grebert, a true legend on our team, has decided to retire after nearly 30 years of service and leadership across global, country and geography roles across the company. Carl shared his thinking with me some time ago, and I’m deepl
Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 17:41:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment method to its portfolio, Xsolla continues to deliver the fast and flexible payment experience Portuguese players expect. Key
Andersen Consulting Adds Collaborating Firm Africa International Advisors20.1.2026 16:30:00 EET | Press release
Andersen Consulting extends its strategy and business transformation capabilities in Africa through a Collaboration Agreement with Africa International Advisors (AIA), a Johannesburg-based firm focusing on enhancing business competitiveness through sector specific insights, innovation and advisory services. Founded in 2002, AIA is a pan-African management consulting firm that delivers strategy-led advisory services with a focus on digital transformation and AI-driven business outcomes. The firm advises clients across sectors including energy and resources, oil and gas, infrastructure, trade and logistics, financial services, banking, and telecom. AIA’s strategic perspective, local credibility, and market access enable it to design and implement solutions that align people, processes, and technology to drive meaningful change. “From the beginning, our mission has been to drive progress through an Africa-centered lens, grounded in the realities and ambitions of the continent,” said Hasna
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom